All In Biotech

Drug Trial Radar · NCT04873362

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,188 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,188

Actual

Start

May 4, 2021

Primary completion

Mar 31, 2027

Study completion Oct 2, 2034

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.

Conditions

  • Breast Cancer

Interventions

  • AtezolizumabDrug

    Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.

  • Trastuzumab EmtansineDrug

    Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.

  • PlaceboDrug

    Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.

  • TrastuzumabDrug

    Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-free Survival (IDFS) in the Full Analysis Set (FAS)Time frame: From baseline until the first occurrence of iDFS event or death, through primary analysis data cut off (approximately 7 years)

Locations

238 sites in 32 countries. Site status is shown where the registry gives one.

  • Alabama Oncology

    Birmingham, Alabama

  • Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center

    Buena, California

  • UCLA Medical Center

    Santa Monica, California

  • Innovation Clinical Research Institute

    Whittier, California

  • Florida Cancer Specialists

    West Palm Beach, Florida

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital

    Carrollton, Georgia

  • University of Iowa

    Iowa City, Iowa

  • New England Cancer Specialists

    Westbrook, Maine

  • The Valley Hospital

    Paramus, New Jersey

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit

    Philadelphia, Pennsylvania

  • The West Clinic

    Germantown, Tennessee

  • Thompson Cancer Survival Center

    Knoxville, Tennessee

  • Mays Cancer Center at UT Health San Antonio MD Anderson Cancer

    San Antonio, Texas

  • Hematology Oncology Associates of Fredericksburg, Inc.

    Fredericksburg, Virginia

  • Virginia Oncology Associates - New Port News

    Newport News, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Virginia Cancer Institute

    Richmond, Virginia

  • Virginia Oncology Associates - Virginia Beach

    Virginia Beach, Virginia

  • Providence Regional Cancer Partnership

    Everett, Washington

  • Kadlec Clinic Hematology and Oncology

    Kennewick, Washington

  • Northwest Medical Specialties

    Tacoma, Washington

  • Macarthur Cancer Therapy Centre

    Campbelltown, New South Wales, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Tiroler Landeskrankenanstalten Ges.M.B.H.

    Innsbruck, Austria

  • Ordensklinikum Linz Barmherzige Schwestern

    Linz, Austria

  • Lkh Salzburg - Univ. Klinikum Salzburg

    Salzburg, Austria

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, Belgium

  • Clinique St. Elizabeth

    Namur, Belgium

  • Crio - Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazil

  • Hospital Sao Rafael - HSR

    Salvador, Estado de Bahia, Brazil

  • Hospital Araujo Jorge

    Goiânia, Goiás, Brazil

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

    Ijuí, Rio Grande do Sul, Brazil

  • Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Sao Lucas - PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Base de Sao Jose do Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda

    São Paulo, São Paulo, Brazil

Showing 40 of 238 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.